Core Viewpoint - The stock of Lai Kai Pharmaceutical-B (02105) opened over 4% higher following the announcement of an exclusive licensing agreement with Qilu Pharmaceutical for the commercialization of the breast cancer candidate drug LAE002 in China [1] Group 1: Licensing Agreement - Lai Kai Pharmaceutical has entered into an exclusive licensing agreement with Qilu Pharmaceutical to accelerate the commercialization of LAE002 (Afuresertib) for HR+/HER2- breast cancer in China [1] - The agreement includes a non-refundable upfront payment of up to RMB 530 million and milestone payments related to clinical development [1] - Additionally, Lai Kai is entitled to receive a tiered sales revenue share from future net sales in China, with the share percentage ranging from over ten percent to over twenty percent [1] Group 2: Clinical Trials - The Phase III clinical trial (AFFIRM-205) for LAE002 is currently progressing as planned, with patient recruitment ongoing [1]
港股异动 | 来凯医药-B(02105)高开逾4% 与齐鲁制药就LAE002订立独家许可协议